NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• NewEdge Advisors cut its Alnylam Pharmaceuticals position by 82.2% in the first quarter, selling 10,701 shares and retaining 2,316 shares valued at approximately $766,000.
• Institutional ownership remains high at 92.97%, with several major investors—including Norges Bank and Qube Research & Technologies—initiating or significantly increasing positions. Director David E. I. Pyott also sold 3,830 shares under a Rule 10b5-1 plan.
• Alnylam reported quarterly EPS of $1.84, beating estimates, while revenue rose 66.9% year over year to $1.29 billion. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $386.62, despite recent target reductions.

NewEdge Advisors LLC decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 82.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,316 shares of the biopharmaceutical company's stock after selling 10,701 shares during the quarter. NewEdge Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $766,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ALNY. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $895,816,000. Qube Research & Technologies Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $369,943,000. AQR Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company's stock valued at $336,009,000 after acquiring an additional 555,759 shares during the last quarter. Orbis Allan Gray Ltd increased its stake in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after acquiring an additional 486,489 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2,221.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company's stock worth $187,116,000 after acquiring an additional 392,668 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $242.61 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The firm has a market capitalization of $32.46 billion, a price-to-earnings ratio of 45.09 and a beta of 0.30. The company has a fifty day simple moving average of $269.15 and a 200-day simple moving average of $298.51. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company's revenue for the quarter was up 66.9% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ALNY shares. Bank of America lowered their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a "buy" rating on the stock in a report on Tuesday, July 14th. Barclays cut their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating for the company in a report on Monday, August 3rd. HC Wainwright decreased their price objective on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Oppenheimer lowered their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating on the stock in a research note on Friday, July 31st. Finally, Sanford C. Bernstein upgraded Alnylam Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $386.62.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source